Metformin & Longevity: Diabetes Drug Linked to Increased Lifespan in Women

A common diabetes medication, metformin, may be linked to increased longevity in women, according to a study published in 2025. Researchers found a potential connection between initiating metformin treatment and a greater chance of reaching age 90.

Metformin and Longevity: The Study Findings

The research, conducted by scientists in the United States and Germany and published in the Journal of Gerontology: Medical Sciences, analyzed data from a large-scale study of postmenopausal women. A total of 438 participants were selected, with half receiving metformin and the other half being treated with sulfonilureas, another type of diabetes medication.

Did You Know? The study followed participants for an average of 14 to 15 years, a period significantly longer than typical clinical trials.

Results indicated that women who began treatment with metformin had a 30% lower risk of dying before the age of 90 compared to those using sulfonilureas. The authors wrote that “Metformin has been shown to target multiple pathways of aging and has been considered a potential drug to extend human lifespan.”

A Potential Geroprotective Drug

Metformin, used for decades, is considered a gerotherapeutic – a medication that may slow down the biological processes of aging. Previous studies suggest it could reduce DNA damage, positively influence genes associated with longevity, and slow the decline of brain function. However, the study notes there is currently no definitive proof that metformin extends human lifespan, and research is ongoing.

Expert Insight: The identification of existing medications with potential anti-aging properties represents a significant shift in medical research, focusing on delaying or preventing age-related diseases rather than solely treating them as they arise.

Study Limitations and Future Research

The study’s authors acknowledge that their research cannot prove a cause-and-effect relationship. The study was not a randomized controlled experiment; participants followed treatment plans recommended by their doctors, rather than being randomly assigned. There was no placebo group.

Researchers suggest that controlled clinical trials could clarify whether metformin has direct effects on longevity. In the context of a globally aging population, there is growing interest in medications that can slow the biological aging process. According to the researchers, “the geroscience hypothesis supports that biological aging is malleable and that slowing it can delay or prevent the onset of age-related diseases.”

Frequently Asked Questions

What was the main finding of the study?

The study found that women who initiated treatment with metformin had a 30% lower risk of dying before the age of 90 compared to those treated with sulfonilureas.

What is a gerotherapeutic?

A gerotherapeutic is a medication that may slow down the biological processes of aging.

Did the study prove that metformin extends lifespan?

No, the study did not prove that metformin extends lifespan, but it suggests a potential link between metformin use and increased longevity in women.

As research into the aging process continues, will findings like these influence preventative healthcare strategies?